~~<i id='351CA3271B'><strike id='351CA3271B'><tt id='351CA3271B'><pre id='351CA3271B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：focus 2025-09-30 23:20:18 - browse：799

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Why rehabilitation engineers need to center patients in their research

focus

explore

knowledge

explore

Wikipedia

MollyFergusonforSTATWhenCherylDaiglestartedcoughinginFebruary2013,shechalkedituptothesneezingandsnif

WSS

To avoid data mishandling cases, universities eye AI and other tools

Robert F. Kennedy is pitching centrism on health, even on abortion

Q&A: Jennifer Adair on making gene therapy available globally

Cancer researcher Catriona Jamieson is sending tumors into space

Element Biosciences CEO lays out genome sequencing strategy

Cholera vaccine supply gets boost as demand surges globally

focus

entertainment

focus

Bright Health sells Medicare Advantage business to Molina

Vaccine advisory panel ACIP left half staffed by HHS

Trump demands the U.S. pay no more for drugs than other countries … again

What should King Charles tell the public about his cancer?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cue Health's Covid

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bird flu in milk supply is likely coming from asymptomatic cows

Walensky prepares to leave CDC — and Congress — behind

Q&A: Jennifer Adair on making gene therapy available globally

explore

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

To avoid data mishandling cases, universities eye AI and other tools

Biogen Alzheimer’s drug launch off to slow start

Exact Sciences stock tumbles despite strong cancer detection sales

Diversity in clinical trials starts with building trust, experts say

Cell therapy fails to slow type 1 diabetes, but safety is established

explore

knowledge

explore

Wikipedia